DPA-713
DPA-713 is a blood-brain barrier-permeable, specific translocator protein (TSPO) ligand. DPA-713 binds exclusively to TSPO without interacting with central benzodiazepine receptors; its binding can be competitively displaced by excess unlabeled TSPO ligands. After 11C labeling, DPA-713 enables sensitive quantitative analysis of TSPO expression associated with microglial activation, allowing differentiation between normal and pathological brain tissues. DPA-713 can be used in studies related to neuroinflammation, neurodegenerative diseases, and recently onset schizophrenia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 386297-97-8
- Formule: C21H26N4O2
- Masse moléculaire:366.47
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Radionuclide-Drug Conjugates (RDCs)
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | IC50 |
>100 μM
Compound: DPA-713
|
Antiproliferative activity against HEK293T cells expressing human TSPO A147T mutant after 48 hrs by BrdU incorporation assay
Antiproliferative activity against HEK293T cells expressing human TSPO A147T mutant after 48 hrs by BrdU incorporation assay
|
[PMID: 30108706] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 386297-97-8
-
Masse moléculaire 366.47
-
Formule C21H26N4O2
-
SMILES
O=C(N(CC)CC)CC=1C(=NN2C1N=C(C=C2C)C)C=3C=CC(OC)=CC3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Boutin H, et al. 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2007 Apr;48(4):573-81. [Content Brief]
[2]. Endres CJ, et al. Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009 Aug;50(8):1276-82. [Content Brief]
[3]. Coughlin JM, et al. In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of CSF and plasma. Translational psychiatry. 2016 Apr 12;6(4):e777. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DPA-713 Related Classifications
HY-W667746 Related Classifications
Powered by Bioz
- DPA-713
- 386297-97-8
- DPA713
- DPA 713
- TSPO
- Radionuclide-Drug Conjugates (RDCs)
- recent-onset schizophrenia
- blood-brain barrier
- neurodegenerative diseases
- neuroinflammation
- translocator protein (TSPO)
- central benzodiazepine receptors
- rat brain tissue
- baboons
- TSPO rs6971 genotype
- microglial activation
- Inhibitor
- inhibitor
- inhibit